BPC-157 Research Peptide

BPC-157 began life in the stomach. In the early 1990s, Predrag Sikirić’s team in the Department of Pharmacology at the University of Zagreb described a larger protective protein in human gastric juice, which they called Body Protection Compound, and the 15-residue stretch now sold as BPC-157 is a partial sequence of it. Unusually for so short a chain, the fragment was reported to stay intact in human gastric juice.

That origin shaped the first experiments. Rat models of damage to the stomach and intestinal lining came first, including mucosal lesions provoked by alcohol and by non-steroidal anti-inflammatory drugs, and the work later widened to fistula, oesophageal and bowel models. By the early 2000s the Croatian company Pliva was testing the peptide in clinical studies for inflammatory bowel disease under the code PL 14736. The Gastrointestinal Research Bundle groups it with KPV and VIP for laboratories working in this area.

Musculoskeletal studies make up a large share of the BPC-157 literature. A much-cited example cut through the rat Achilles tendon a few millimetres above the heel bone, leaving a wide gap between the two ends, and then followed recovery for two weeks. Against controls, treated animals showed a higher load at failure and a higher Young’s modulus, better Achilles functional index scores, and more fibroblasts, reticulin and collagen in the healing gap under the microscope (Learn more).

The same style of experiment has since been applied to transected muscle, ligament injuries and the myotendinous junction where muscle meets tendon, largely by the Zagreb group. Newer studies have begun to put BPC-157, TB-500 and the pair together in one rat Achilles repair model, which is the thinking behind the Wolverine Stack.

A team at Chang Gung University in Taiwan studied what happens inside fibroblasts taken from rat Achilles tendon. In their experiments BPC-157 did not make the cells divide any faster, yet it sped up the outgrowth of cells from small tendon explants, improved survival when cultures were stressed with hydrogen peroxide, and increased migration through a transwell filter as the concentration rose.

Treated fibroblasts also flattened out across the dish more quickly and assembled more filamentous actin, the cable-like network a cell uses to crawl. Western blotting tied this to greater activation of focal adhesion kinase and paxillin, the proteins that anchor that network to the spots where a cell grips its surface. A follow-up from the same laboratory found the growth hormone receptor among the genes most strongly switched on in these cells.

Healing tissue needs a blood supply, so angiogenesis is one of the busiest BPC-157 research themes. One 2017 study ran it through several angiogenesis tests at once: vessel density increased in the chick chorioallantoic membrane assay and in endothelial tube-formation tests, and laser Doppler scanning showed faster return of blood flow in an ischaemic rat hind-limb model (Learn more).

In human vascular endothelial cells, BPC-157 raised levels of the receptor VEGFR2 while leaving its usual partner VEGF-A unchanged, and it pushed the receptor to be taken up into the cell. Blocking that uptake with dynasore also blunted the downstream VEGFR2–Akt–eNOS signalling. Since eNOS is the enzyme that makes nitric oxide in blood-vessel linings, the finding sits neatly beside the Zagreb group’s long-running interest in how BPC-157 interacts with the nitric oxide system.

Reviews of the animal literature regularly report lower inflammatory cytokine activity in BPC-157 studies, and critical reviews published recently have pulled together its rodent ischaemia–reperfusion work, where oxidative stress, inflammation and nitric oxide responses are measured side by side. Laboratories building inflammation models often compare it with smaller signalling peptides such as KPV.

Good research also means being clear about the gaps. Formal preclinical pharmacokinetic work reports a plasma half-life of under 30 minutes, which sits awkwardly beside effects lasting hours or days in animal studies. Review titles such as “Regeneration or Risk?” show how actively the field is debating what the animal data mean, and settling those questions is a big part of why BPC-157 stays so widely studied.